Kovack Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kovack Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$978K	Sell	7,639 -138	-2%	-$17.2K	0.05%	374
2025 Q4	$948K	Buy	7,777 +4,158	+115%	+$477K	0.04%	398
2025 Q3	$363K	Sell	3,619 -1,199	-25%	-$108K	0.03%	413
2025 Q2	$400K	Sell	4,818 -541	-10%	-$43.2K	0.04%	387
2025 Q1	$435K	Sell	5,359 -787	-13%	-$70.3K	0.05%	337
2024 Q4	$553K	Buy	6,146 +1,597	+35%	+$155K	0.05%	286
2024 Q3	$449K	Sell	4,549 -705	-13%	-$69.3K	0.05%	328
2024 Q2	$487K	Buy	5,254 +1,292	+33%	+$116K	0.05%	306
2024 Q1	$376K	Sell	3,962 -2,257	-36%	-$209K	0.05%	307
2023 Q4	$555K	Sell	6,219 -10,025	-62%	-$744K	0.07%	278
2023 Q3	$1.19M	Buy	16,244 +1,422	+10%	+$114K	0.17%	130
2023 Q2	$1.23M	Buy	14,822 +11,404	+334%	+$954K	0.16%	134
2023 Q1	$260K	Buy	+3,418	New	+$284K	0.04%	444
2022 Q3	–	Sell	-11,112	Closed	-$825K	–	649
2022 Q2	$825K	Buy	+11,112	New	+$834K	0.11%	204
2017 Q1	–	Sell	-3,667	Closed	-$217K	–	328
2016 Q4	$217K	Buy	+3,667	New	+$226K	0.1%	219

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kovack Advisors's XBI Position: Q1 2026 in Review

Kovack Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.8% in Q1 2026, selling an estimated $17.2K and leaving 7,639 shares worth $978K. The position accounts for 0.05% of the portfolio, ranked #374.

Kovack Advisors first reported a position in XBI in Q4 2016 and has held it in 15 quarters since. The position peaked at $1.23M in Q2 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Kovack Advisors held 7,639 shares of State Street SPDR S&P Biotech ETF worth $978K as of Q1 2026.
Kovack Advisors sold 138 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $17.2K.
State Street SPDR S&P Biotech ETF made up 0.05% of Kovack Advisors's portfolio in Q1 2026, its #374 holding.
Kovack Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 15 quarters since.
Kovack Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.23M in Q2 2023.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.